Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABUS NASDAQ:ARCT NASDAQ:ATHX NASDAQ:ATXI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABUSArbutus Biopharma$3.13-0.3%$3.31$2.71▼$4.73$599.49M1.2949,521 shs894,105 shsARCTArcturus Therapeutics$13.50-0.3%$12.79$8.04▼$25.88$366.12M2.27416,565 shs278,097 shsATHXAthersys$0.00$0.01▼$1.99$833K-0.91.77 million shsN/AATXIAvenue Therapeutics$0.42+17.1%$0.26$0.17▼$3.93$1.34M-0.08130,477 shs8,345 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABUSArbutus Biopharma+0.32%-4.27%-8.99%-0.32%-16.93%ARCTArcturus Therapeutics+5.37%-6.49%+10.26%+28.58%-44.23%ATHXAthersys0.00%0.00%0.00%0.00%-56.52%ATXIAvenue Therapeutics-0.42%+42.38%+38.27%+35.35%-89.84%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABUSArbutus Biopharma2.1436 of 5 stars3.50.00.00.02.72.50.6ARCTArcturus Therapeutics1.9584 of 5 stars3.60.00.00.01.92.50.6ATHXAthersysN/AN/AN/AN/AN/AN/AN/AN/AATXIAvenue Therapeutics2.0686 of 5 stars0.04.00.04.61.00.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABUSArbutus Biopharma 3.00Buy$5.5075.72% UpsideARCTArcturus Therapeutics 3.11Buy$54.00300.00% UpsideATHXAthersys 0.00N/AN/AN/AATXIAvenue Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ABUS, ATHX, ARCT, and ATXI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/2/2025ARCTArcturus TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform7/2/2025ARCTArcturus TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$32.00 ➝ $35.005/28/2025ARCTArcturus TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$32.005/14/2025ARCTArcturus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$50.00 ➝ $45.005/13/2025ARCTArcturus TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/13/2025ARCTArcturus TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$68.00 ➝ $66.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABUSArbutus Biopharma$6.17M97.16N/AN/A$0.51 per share6.14ARCTArcturus Therapeutics$152.31M2.40N/AN/A$8.90 per share1.52ATHXAthersys$146K0.00N/AN/A($1.33) per share0.00ATXIAvenue TherapeuticsN/AN/AN/AN/A$1.92 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABUSArbutus Biopharma-$69.92M-$0.41N/AN/AN/A-1,196.64%-75.51%-55.81%8/7/2025 (Estimated)ARCTArcturus Therapeutics-$80.94M-$2.53N/AN/AN/A-47.47%-27.41%-19.01%8/4/2025 (Estimated)ATHXAthersys-$72.53M-$2.03N/AN/AN/AN/AN/A-223.03%N/AATXIAvenue Therapeutics-$10.38M-$7.490.02∞N/AN/A-471.57%-296.50%8/7/2025 (Estimated)Latest ABUS, ATHX, ARCT, and ATXI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025ABUSArbutus Biopharma-$0.02N/AN/AN/AN/AN/A8/4/2025Q2 2025ARCTArcturus Therapeutics-$1.11N/AN/AN/A$17.64 millionN/A5/14/2025Q1 2025ABUSArbutus Biopharma-$0.09-$0.13-$0.04-$0.13$2.54 million$1.76 million5/12/2025Q1 2025ARCTArcturus Therapeutics-$1.58-$0.52+$1.06-$0.52$25.64 million$29.38 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABUSArbutus BiopharmaN/AN/AN/AN/AN/AARCTArcturus TherapeuticsN/AN/AN/AN/AN/AATHXAthersysN/AN/AN/AN/AN/AATXIAvenue TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABUSArbutus Biopharma0.046.016.01ARCTArcturus Therapeutics0.065.645.64ATHXAthersysN/A0.060.06ATXIAvenue TherapeuticsN/A2.702.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABUSArbutus Biopharma43.79%ARCTArcturus Therapeutics94.54%ATHXAthersys19.35%ATXIAvenue Therapeutics17.34%Insider OwnershipCompanyInsider OwnershipABUSArbutus Biopharma20.30%ARCTArcturus Therapeutics16.60%ATHXAthersys0.03%ATXIAvenue Therapeutics1.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABUSArbutus Biopharma90191.53 million152.65 millionOptionableARCTArcturus Therapeutics18027.12 million22.62 millionOptionableATHXAthersys2461.72 million61.70 millionNo DataATXIAvenue Therapeutics43.18 million2.02 millionNot OptionableABUS, ATHX, ARCT, and ATXI HeadlinesRecent News About These Companies'Large police presence' along 10th Avenue South bridgeJuly 18 at 3:17 AM | krtv.comKRedesign plans proposed for a safer, more walkable Patton AvenueJuly 18 at 3:17 AM | msn.comMan, 69, dead after crash at intersection of West Yamato Road and Congress AvenueJuly 18 at 3:17 AM | wptv.comW2 dead, 1 critically injured in shooting on Haskell AvenueJuly 18 at 3:17 AM | www2.ljworld.comWWhat $1,887,000 bought on Del Sol Avenue: An Alameda County homeJuly 18 at 3:17 AM | mercurynews.comMThree-car crash shuts down Columbia Avenue in Lancaster CountyJuly 18 at 3:17 AM | msn.comPolice arrest suspect who robbed banks on Atlantic Avenue, Linton Boulevard in Delray BeachJuly 18 at 3:17 AM | wflx.comWHistoric Center Avenue home could get new life as Bay City bed and breakfastJuly 18 at 3:17 AM | msn.comFinding solutions for safety concerns along Central AvenueJuly 18 at 3:17 AM | kob.comKGrand Rapids planning $1M reconstruction project of Plainfield AvenueJuly 17 at 6:30 AM | msn.comWho’s New on Madison Avenue and Who’s on Their WayJuly 17 at 6:30 AM | yahoo.comSpokane Street and Poleline Avenue roundabout to get a faceliftJuly 17 at 6:30 AM | cdapress.comCPolice presence reported on Pasadena Avenue in Arden-ArcadeJuly 17 at 6:30 AM | msn.comStylish sight on Worth Avenue in Palm Beach for Tribal Fashion photo shootJuly 17 at 6:30 AM | palmbeachdailynews.comPWoman injured in rollover car crash on Lake AvenueJuly 17 at 6:30 AM | whec.comWHow is the Plainfield Avenue construction project going?July 17 at 6:30 AM | woodtv.comWAsheville announces completion of Patton Avenue stormwater, sidewalk projectsJuly 17 at 6:30 AM | msn.comNew Braunfels Announces Castell Avenue Closure for Resurfacing Traffic Delays ExpectedJuly 17 at 6:30 AM | hoodline.comHCrews wait for concrete to cure on Plainfield AvenueJuly 17 at 6:30 AM | msn.comPart of Forest Avenue in Des Moines closed for natural gas leakJuly 16 at 6:49 PM | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABUS, ATHX, ARCT, and ATXI Company DescriptionsArbutus Biopharma NASDAQ:ABUS$3.13 -0.01 (-0.32%) Closing price 04:00 PM EasternExtended Trading$3.16 +0.03 (+0.96%) As of 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.Arcturus Therapeutics NASDAQ:ARCT$13.50 -0.04 (-0.30%) Closing price 04:00 PM EasternExtended Trading$13.65 +0.15 (+1.14%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Athersys NASDAQ:ATHXAthersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio.Avenue Therapeutics NASDAQ:ATXI$0.42 +0.06 (+17.06%) As of 03:57 PM EasternAvenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
